These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 7661033)

  • 1. Benzbromarone and fenofibrate are lipid lowering and uricosuric: a possible key to metabolic syndrome?
    Gresser U; Gathof BS; Gross M
    Adv Exp Med Biol; 1994; 370():87-90. PubMed ID: 7661033
    [No Abstract]   [Full Text] [Related]  

  • 2. Uricosuric effect of fenofibrate in healthy volunteers.
    Desager JP; Hulhoven R; Harvengt C
    J Clin Pharmacol; 1980 Oct; 20(10):560-4. PubMed ID: 7440763
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of the addition of micronised fenofibrate on uric acid metabolism in patients receiving indapamide.
    Achimastos A; Liberopoulos E; Nikas S; Bairaktari E; Miltiadous G; Tsimihodimos V; Elisaf M
    Curr Med Res Opin; 2002; 18(2):59-63. PubMed ID: 12017210
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The uricosuric action of halofenate (MK-185) in patients with hyperuricemia or uncomplicated primary gout and hyperlipidemia.
    Hutchison JC; Wilkinson WH
    Atherosclerosis; 1973; 18(3):353-62. PubMed ID: 4584481
    [No Abstract]   [Full Text] [Related]  

  • 5. Stronger Uricosuric Effects of the Novel Selective URAT1 Inhibitor UR-1102 Lowered Plasma Urate in Tufted Capuchin Monkeys to a Greater Extent than Benzbromarone.
    Ahn SO; Ohtomo S; Kiyokawa J; Nakagawa T; Yamane M; Lee KJ; Kim KH; Kim BH; Tanaka J; Kawabe Y; Horiba N
    J Pharmacol Exp Ther; 2016 Apr; 357(1):157-66. PubMed ID: 26907620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Uricosuric agent].
    Ohno I
    Nihon Rinsho; 2008 Apr; 66(4):743-7. PubMed ID: 18409525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of urate-lowering therapies on renal handling of uric acid.
    Ma L; Wei L; Chen H; Zhang Z; Yu Q; Ji Z; Jiang L
    Clin Rheumatol; 2016 Jan; 35(1):133-41. PubMed ID: 25373449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of fenofibrate in combination with urate lowering agents in patients with gout.
    Lee YH; Lee CH; Lee J
    Korean J Intern Med; 2006 Jun; 21(2):89-93. PubMed ID: 16913436
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Micronised fenofibrate: a review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia.
    Adkins JC; Faulds D
    Drugs; 1997 Oct; 54(4):615-33. PubMed ID: 9339964
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gout due to xanthine derivatives.
    Toda K; Goriki K; Ochiai M; Tokunou H; Uehara S; Takahashi H; Okusaki K
    Br J Rheumatol; 1997 Oct; 36(10):1131-2. PubMed ID: 9374937
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinical evaluation of benzbromarone: a new uricosuric drug.
    Sorensen LB; Levinson DJ
    Arthritis Rheum; 1976; 19(2):183-90. PubMed ID: 1259799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of losartan and benzbromarone on the level of human urate transporter 1 mRNA.
    Nindita Y; Hamada T; Bahrudin U; Hosoyamada M; Ichida K; Iwai C; Urashima S; Kuwabara M; Utami SB; Mizuta E; Yamada K; Igawa O; Shigemasa C; Ninomiya H; Tsuchihashi T; Hisatome I
    Arzneimittelforschung; 2010; 60(4):186-8. PubMed ID: 20486468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increasing high-density lipoprotein cholesterol: an update on fenofibrate.
    Després JP
    Am J Cardiol; 2001 Dec; 88(12A):30N-36N. PubMed ID: 11788128
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome.
    Watts GF; Barrett PH; Ji J; Serone AP; Chan DC; Croft KD; Loehrer F; Johnson AG
    Diabetes; 2003 Mar; 52(3):803-11. PubMed ID: 12606523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Two cases in whom pyrazinamide does not inhibit the uricosuric action of benzbromarone.
    Yamamoto T; Moriwaki Y; Takahashi S; Suda M; Agbedana EO; Higashino K
    Nephron; 1992; 61(4):432-4. PubMed ID: 1501741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Uric acid-lowering treatment with benzbromarone in patients with heart failure: a double-blind placebo-controlled crossover preliminary study.
    Ogino K; Kato M; Furuse Y; Kinugasa Y; Ishida K; Osaki S; Kinugawa T; Igawa O; Hisatome I; Shigemasa C; Anker SD; Doehner W
    Circ Heart Fail; 2010 Jan; 3(1):73-81. PubMed ID: 19933411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of comicronised fenofibrate on lipid and insulin sensitivity in patients with polymetabolic syndrome X.
    Idzior-Walus B; Sieradzki J; Rostworowski W; Zdzienicka A; Kawalec E; Wójcik J; Zarnecki A; Blane G
    Eur J Clin Invest; 2000 Oct; 30(10):871-8. PubMed ID: 11029601
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum CRP in patients with gout and effects of benzbromarone.
    Okuda C; Koyama H; Tsutsumi Z; Yamamoto A; Kurajoh M; Moriwaki Y; Yamamoto T
    Int J Clin Pharmacol Ther; 2011 Mar; 49(3):191-7. PubMed ID: 21329621
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effect of benzbromarone on serum uric acid level and uric acid excretion of patients with gout].
    Zöllner N; Griebsch A; Fink JK
    Dtsch Med Wochenschr; 1970 Nov; 95(48):2405-12. PubMed ID: 5480261
    [No Abstract]   [Full Text] [Related]  

  • 20. Control of uric acid excretion.
    Steele TH
    N Engl J Med; 1971 May; 284(21):1193-6. PubMed ID: 4929385
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.